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ABSTRACT
Forty-nine patients with intermediate- and high-risk aggressive non-Hodgkin lymphoma underwent autolo-
gous hematopoietic stem cell transplantation (autoHSCT) using the regimen of busulfan (Bu), cyclophosph-
amide (Cy), and etoposide (E) that was originally developed for allogeneic HSCT. Eighteen patients treated
before 1999 received Cy 2.5 g/m2 on days3 to2 and E 1800 mg/m2 on day3 after oral (PO) administration
of Bu 1 mg/kg every 6 hours  4 days for a total of 16 doses beginning on day 7. After April 1999, 31 patients
similar in all pretransplantation risk assessments received the same regimen except that intravenous (IV) Bu
was substituted for PO Bu and pharmacokinetic-directed (PKD) dosing was attempted to achieve an area under
the concentration time curve of 1000-1500 mol/min for each dose. Nonrelapse mortality was 28% for PO Bu
patients versus 3% for the IV PKD group (P .01, chi-square test). Actuarial 5-year overall survivals were 28%
for patients who received the PO Bu regimen and 58% for patients who received the IV Bu regimen (P  .010,
log-rank test), and progression-free survivals were 17% and 50%, respectively (P  .008, log-rank test). After
substitution of PKD IV Bu in the BuCyE regimen, we observed lower nonrelapse mortality with increased
overall and progression-free survivals in patients with intermediate- and high-risk aggressive non-Hodgkin
lymphoma who underwent autoHSCT.
© 2006 American Society for Blood and Marrow Transplantation
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eNTRODUCTION
High-dose chemotherapy followed by autologous
tem cell rescue is the standard of care for suitable
atients with aggressive non-Hodgkin lymphoma
NHL) after failure of primary therapy [1]. Studies
onducted in the early 1980s demonstrated that patients
ith at least partial remission of relapsed disease after i
70yclic submyeloablative chemotherapy (sensitive relapse,
ntermediate risk [2]) have a 35%-50% long-term sur-
ival rate with cyclophosphamide (Cy)/total body irradi-
tion (TBI) or various carmustine (BCNU)-based high-
ose chemotherapy regimens [3-6]. The addition of
toposide (E) to BCNU/Cy [7] and to Cy/TBI [8]
mproved the effectiveness of hematopoietic stem cell
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Autologous HSCT for NHL with IV Busulfan 771ransplantation (HSCT) in the treatment of NHL. In
landmark randomized trial [4], patients with sensi-
ive relapse achieved a 53% long-term survival with a
egimen of BCNU with Cy, cytosine arabinoside, and
versus a 32% long-term survival with continued
onmyeloablative chemotherapy (P  .038). Recent
eports of results in trials of patients with mixed in-
ermediate- and higher-risk patients [9] and registry
ata [10] put overall survival (OS) and progression-
ree survival (PFS) in the 45%-50% range. However,
atients with more advanced or resistant disease have
ong-term survival rates as low as 14% [3].
Busulfan (Bu)-based preparative regimens are
ommonly used in allogeneic HSCT [11-13] but
ave been studied less frequently in autologous
SCT (autoHSCT). Copelan et al [14], Hanel et al
15], and Kroger et al [16] separately reported a long-
erm OS of 45% after autoHSCT for patients with
ggressive NHL when using a BuCyE preparative
eveloped previously for allogeneic HSCT [17].
The difﬁculty in predicting and assessing dose
elivered with oral (PO) administration of high-dose
u in preparative regimens for HSCT results in a
igniﬁcant risk of lethal pulmonary or hepatic toxicity
ue to inadvertent overdosing [18-20] and the poten-
ial for graft failure [21] or persistent malignant dis-
ase after transplantation due to under dosing [22,23].
he range of an acceptable target area under the curve
AUC) of Bu for different clinical situations in HSCT to
void these causes of treatment failure is increasingly
ell deﬁned [21-26]. Studies done at the University of
labama at Birmingham (UAB) have demonstrated that
single-compartment, ﬁrst-order elimination model
ell describes the pharmacokinetics (PK) of intravenous
IV) Bu [27], and a limited sampling strategy that
llows accurate and inexpensive AUC determination
as been developed [24,27]. Our results demonstrate
hat simple PK on a test dose can accurately predict
UC for subsequent doses in a therapeutic regimen
28,29].
Since 1991 BuCyE has been the standard prepar-
tive regimen for patients with intermediate- and
igh-risk NHL undergoing autoHSCT on the Bone
arrow Transplantation service at UAB. Before the
vailability of the IV formulation of Bu in March
999, the PO formulation was used in the combina-
ion at a dose of 1 mg/kg every 6 hours (q6h) for a
otal of 16 doses. The mean AUC achieved with this
ose of PO Bu is approximately 1200 mol/min but
anges from 500 to 1800 mol/min [19,20,30]. Since
pril 1999 we have been using IV Bu with progres-
ively evolving PK-directed (PKD) therapy to target
n AUC of 1000-1500 mol/min in the otherwise
dentical regimen. This has provided us an opportu-
ity to compare the outcomes of autoHSCT using the
uCyE preparative regimen with PO with those of
KD IV Bu. aETHODS
Forty-nine consecutive patients with intermediate
nd high-risk aggressive NHL underwent autoHSCT
sing the BuCyE regimen at UAB from August 1994
o September 2003. All patients were required to have
heir histologic diagnosis and histologic conﬁrmation
f the most recent recurrence conﬁrmed at UAB, a
ormal bone marrow aspirate and biopsy since the
ost recent recurrence, a carbon monoxide diffusing
apacity corrected for anemia 70% of predicted, left
entricular ejection fraction 50% or an increase of
10% with exercise, renal and hepatic functions 2
imes the upper limit of normal, and Eastern Coop-
rative Oncology Group performance status score3.
ll patients signed informed consent for high-dose
hemotherapy followed by autoHSCT and written
nformed consent for the use of their records for
esearch in compliance with UAB institutional review
oard requirements.
ematopoietic Stem Cell Mobilization
nd Collection
All patients in the PO group and 26 of 31 patients
n the PKD IV Bu group underwent transplantation
ith peripheral blood hematopoietic stem cells (HSCs)
obilized with granulocyte colony-stimulating factor
G-CSF) alone at a dose of 10 g · kg1 · d1 for 4 days,
eginning pheresis on day 5, and continuing daily until
ollection of 7  108 nucleated cells/kg. Before April
001, the same standard was used for the PKD IV Bu
atients. At that time CD34 cell counting became rou-
ine and G-CSF was continued to an absolute CD34
ell count 5/L for a white blood cell count
10 000/L or 10/L for a white blood cell count
1000/L, and collections continued daily until 2 
06 CD34 cells/kg were collected. Subsequent to April
001, 5 of 20 patients in the PKD IV Bu group received
hemotherapy plus G-CSF at the same daily dose to the
ame CD34 cell target. Three patients received Cy 2.5
/m2 for failure to mobilize with G-CSF alone and 2
atients received Cy at the same dose plus E 600 mg/m2
or progressing disease after salvage chemotherapy.
SCs were collected from all patients by using high-
olume leukophoresis through a large-bore central ve-
ous catheter on Cobe Strectra (Cobe Laboratories,
nc., Lakewood, CO) equipment.
reatment Regimen
The preparative regimen before autoHSCT con-
isted of PO or IV Bu from day7 to day4 followed
y Cy (2.5 g/m2) intravenously over 2 hours daily on
ays 3 and 2 and E (1800 mg/m2) infused intra-
enously over 4 hours on day 3 (Figure 1). HSCs
ere infused on day 0. Eighteen patients treated
hrough March 1999 received PO Bu 1 mg/kg q6h for
total of 16 doses with no PK monitoring. Thirty-one
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C. Aggarwal et al.772atients treated after March 1999 received IV Bu on
he same schedule, with minor adjustments to facili-
ate PKD therapy.
IV Bu was administered as a 2-hour infusion using
n increasingly sophisticated approach to PKD ther-
py, with a target AUC of 1250 mol/min. The goal
as to achieve a level between 1000 and 1500. Further
ose adjustments were made if the conﬁrmatory levels
ere outside these parameters. Before March 2001, 11
atients received dose 1 of IV Bu at 27.5 mg/m2 and
ad doses 8-16 adjusted based on dose 1 AUC. Be-
ween March 2001 and November 2002, 15 patients
ad dose 1 determined by the AUC of a test dose of 15
g/m2 given as an outpatient 48 hours previously and
oses 8-16 adjusted based on dose 1 AUC. Since
ecember 2002 we have given all adults a ﬁxed dose of
2.5 mg for dose 1 given as an outpatient 48 hours
efore beginning doses 2-16 given on a q6h schedule.
sing this latest approach, a target AUC of 1250
mol/min, and careful concomitant medication con-
rol, we have been able to achieve an AUC between
000 and 1500 mol/min for 96% of patients [28,29].
K Determination
Collection of samples for PK was done according
o a limited sampling strategy developed at UAB [27].
lood samples were collected at 15, 60, 120, 180, and
40 minutes after the end of infusion, kept on wet ice
ntil all samples were collected, and then plasma was
eparated and frozen. Frozen plasma was shipped on
ry ice to the Seattle Cancer Care Alliance Clinical
harmacokinetics Laboratory (Seattle, Wash) for
u level determination. The AUC was calculated by
sing the single-compartment, ﬁrst-order elimina-
ion model in WinNonlin 2.5 or 3.0 (Pharsight
orporation, Mountain View, Calif). The coefﬁ-
ient of variance for ﬁt to model was routinely 5%.
upportive Care
Phenytoin at a dose of 600 mg/d for the duration
f Bu administration was given to prevent Bu-induced
igure 1. Schema for high-dose BuCyE preparative regimen for
utoHSCT for NHL.eizures before April 2003. However, decreasing Bu bevels over time, sometimes with documentation of
ncreasing phenytoin levels, was seen, as previously
een reported by Hassan et al [31]. Since that time,
orazepam in a PO dose of .05 mg q6h beginning the
vening before the ﬁrst dose of Bu has been used [32].
roepithelial prophylaxis for Cy administration con-
isted of hyperhydration and mesna. G-CSF at a daily
ose of 250 g/m2 was started on day 3 after trans-
lantation and continued until the absolute neutrophil
ount was 2.0  103/L. Antiemetics, blood com-
onents, antibacterial and antifungal antibiotics, and
ther supportive care measures were used according
o consensus standard of care documented in contin-
ously updated guidelines for the Bone Marrow
ransplantation program at UAB. However, during
he 10 years reviewed for this report, these changed
ittle. The empiric antibiotic regimen included ami-
oglycosides and amphotericin frequently for refrac-
ory neutropenic fever. No patient received an echi-
ocandin antifungal agent and only 1 received a
econd-generation imidazole (voriconazole), and the
latelet transfusion algorithm did not change.
ngraftment
Engraftment was deﬁned as occurring on the ﬁrst
f 3 days of an absolute neutrophil count .5 
09/L. If engraftment by this deﬁnition had not been
ttained by day 28, in the absence of persistent or
ecurrent malignancy in the bone marrow, the patient
as considered to have primary graft failure.
elapse and Mortality
Relapse and progressive disease were deﬁned as
ccurring on the day of ﬁrst documentation of signs or
ymptoms ultimately determined to be due to relapse
r progression. Death after relapse or progression was
esignated as due to primary disease. Nonrelapse
ortality (NRM) was scored based on data of the
ypes submitted to Center for International Blood and
arrow Transplant Research (CIBMTR) and com-
iled into major categories by organ system ﬁrst to fail
pulmonary, cardiac, etc) if a more speciﬁc syndrome
r infectious agent could not be identiﬁed.
tatistics
The principal endpoints in the study included OS
nd PFS. Events included treatment failure (detection
f disease progression or relapse) and death. Survival
ime of patients who were alive at most recent fol-
ow-up was censored as of that date. The PFS times of
atients were censored as of the date they were last
ocumented to be alive and free of relapse. OS and
FS curves were produced using the product limit
ethod of Kaplan and Meier [33]. Statistical signiﬁ-
ance of differences observed in these time event distri-
utions was assessed with log-rank test [34]. Differences
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Autologous HSCT for NHL with IV Busulfan 773nNRMbetween the 2 groups were statistically analyzed
ith chi-square test on raw data and log-rank test in life
able censored for competing endpoints. All reported P
alues are 2-sided. The date of ﬁnal follow-up was
eﬁned as a physician visit to conﬁrm relapse and
urvival status. As of September 30, 2005, all but 2
atients had had a follow-up physician visit to conﬁrm
tatus after 2 years of follow-up.
ESULTS
Demographics, comorbidities, disease subtype,
revious chemotherapy, and status at HSCT of pa-
ients in the PKD IV and PO Bu groups were similar
Table 1). Median ages were 51 years (range, 19-68) in
he PKD IV Bu group and 53 years (range, 18-69
ears) in the PO Bu group. There were twice as many
en as women (20 versus 11) in the PKD IV Bu
roup. Twenty-four patients (77%) in the PKD IV Bu
roup and 16 patients (89%) in the PO group had
iffuse large B-cell lymphoma. The PKD IV Bu group
lso contained 1 patient (3%) with Burkitt lymphoma,
patients (6%) with mantle cell lymphoma, 3 patients
10%) with T-cell lymphoma, and 1 patient (3%) with
arge cell anaplastic lymphoma. The PO Bu group had
patient (6%) with mantle cell lymphoma and 1
atient (6%) with large cell immunoblastic lymphoma.
Speciﬁc risk factors for transplantation outcome
ere also remarkably similar between groups. The stage
t diagnosis was IV for 13 patients (42%) in the PKD IV
roup and 6 (33%) in the PO group. The remaining
atients in both groups were stage III at diagnosis. In
he PKD IV Bu group, 21 of 31 patients (68%) had
-9 months of chemotherapy before autoHSCT, 8
atients (26%) had 9 months of chemotherapy, and
patients (6%) had 6 months of chemotherapy. In
he PO Bu group, 12 of 18 patients (67%) had 6-9
onths of chemotherapy before autoHSCT, 6 pa-
ients (33%) had 9 months of chemotherapy, and 1
atient (6%) had 6 months of chemotherapy before
utoHSCT. The number of previous chemotherapeutic
egimens among patients before autoHSCT was vari-
ble. In the PKD IV Bu group, 6 patients (19%) received
previous chemotherapeutic regimen, 17 patients (55%)
eceived 2 previous chemotherapeutic regimens, 6 pa-
ients (19%) received 3 previous chemotherapeutic reg-
mens, and 2 patients (6%) were administered 3 pre-
ious chemotherapeutic regimens. In the PO Bu group,
patient (6%) received 1 previous chemotherapeutic
egimen, 14 patients (76%) received 2 previous che-
otherapeutic regimens, and 3 patients (17%) re-
eived 3 previous chemotherapeutic regimens.
Seventeen patients (55%) in the PKD IV group
ad The American Society for Blood and Bone Mar-
ow Transplantation intermediate risk versus 11 pa-
ients (61%) in the PO group. The remaining patients rn both groups were at high risk. The percentage of
atients in each group whose status was “sensitive
able 1. Risk Factors for Outcome of HSCT for 49 Patients with
ntermediate- and High-Risk Undergoing HSCT with PKD IV versus
O Bu in the BuCyE Preparative Regimen*
PKD IV
(n  31)
PO
(n  18)
isk factors at diagnosis
Male 20 (65%) 9 (50%)
Female 11 (35%) 9 (50%)
Age, y
<45 7 (23%) 4 (22%)
45-60 17 (55%) 11 (61%)
>60 7 (23%) 3 (17%)
Age range 19–68 18–69
Median age 51 53
Histology
Diffuse large B cell 24 (77%) 16 (89%)
Mantle cell 2 (6%) 1 (6%)
T cell 3 (10%) 0 (0%)
Burkitt 1 (3%) 0 (0%)
Large cell anaplastic 1 (3%) 0 (0%)
Large cell immunoblastic 0 (0%) 1 (6%)
isk factors during primary therapy
Age-adjusted IPI score before salvage
Low 0 (0%) 0 (0%)
Low/intermediate 9 (29%) 6 (33%)
High/intermediate 7 (23%) 5 (28%)
High 2 (6%) 1 (6%)
Unknown 13 (42%) 6 (33%)
Months of prior chemotherapy
<6 2 (6%) 1 (6%)
6-9 21 (68%) 12 (67%)
>9 8 (26%) 6 (33%)
No. of prior chemotherapy regimens
1 6 (19%) 1 (6%)
2 17 (55%) 14 (78%)
3 6 (19%) 3 (17%)
>3 2 (6%) 0 (0%)
isk factors at HSCT
Status at transplantation
Relapse sensitive 12 (39%) 7 (39%)
Complete remission 2/3 4 (13%) 4 (22%)
First partial remission 1 (3%) 0 (0%)
Total ASBMT intermediate risk 17 (55%) 11 (61%)
Relapse resistant 5 (16%) 1 (6%)
Primary induction failure 5 (16%) 3 (17%)
Relapse untreated 4 (13%) 3 (17%)
Total ASBMT high risk 14 (45%) 7 (39%)
LDH at transplantation
Normal 22 (71%) 12 (67%)
Abnormal 9 (29%) 6 (33%)
Abnormal range 249–631 247–633
Abnormal median 308 418
KPS at transplantation
100 4 (13%) 0 (0%)
90 17 (55%) 8 (44%)
80 8 (26%) 8 (44%)
70 1 (3%) 1 (6%)
60 0 (0%) 1 (6%)
<60 0 (0%) 0 (0%)
IPI indicates International Prognostic Index; LDH, lactate dehy-
drogenase; KPS, karnofsky performance status.elapse” was identical at 39% and comprised the larg-
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C. Aggarwal et al.774st single subgroup. Because patients were referred to
AB for autoHSCT in many cases after treatment for
elapse or primary treatment failure and lactate dehy-
rogenase had not been obtained before the salvage
egimen for primary induction failure or relapse, pre-
alvage age-adjusted International Prognostic Index
cores [35] were not available for 13 of the 31 in the
KD IV group and 6 of the 18 patients in the PO
roup. In the PKD IV Bu group, 9 of the 31 patients
29%) were in the low-/intermediate-risk group, 7
atients (23%) were in the high-/intermediate-risk
roup, and 2 patients (6%) were in the high-risk
roup. In the PO Bu group, 6 of the 18 patients (33%)
ere in the low-/intermediate-risk group, 5 patients
28%) were in the high-/intermediate-risk group, and
patient (6%) was in the high-risk group. No patient
n either group was in the low-risk group. Just before
he preparative regimen, Karnofsky performance sta-
us was 80 for 80% of both groups and only 1
atient (in the PO group) had a Karnofsky perfor-
ance status 70.
ngraftment and Length of Hospital Stay
Time to engraftment and length of hospital stay
ere also similar in the 2 groups. Patients in the PKD
V group underwent engraftment at a median of 11
ays (range, 6-16 days) and those in the PO Bu group
t 13 days (range, 10-21 days; Table 2).
Median inpatient hospital stays were 24 days (range,
6-41 days) for patients receiving the PKD IV Bu regi-
en followed by autoHSCT and 27 days (range, 19-56
ays) for those receiving PO Bu (Table 2).
ortality
Mortality was considered disease related if relapse
r progression of disease was documented before
eath. There were 5 deaths not secondary to relapse
mong the 18 patients in the PO Bu group and 1 death
ot secondary to relapse among the 31 patients in the
KD IV Bu group (P  .01, chi-square test; Table 3).
able 2. Results: Hospital Inpatient Days and Hematopoietic
ngraftment in NHL of 49 Patients with Intermediate- and
igh-Risk NHL Undergoing HSCT with PKD IV Bu in the
uCyE Preparative Regimen
PKD IV
(n  31)
PO
(n  18)
npatient days
Median 23 24
Mean 24 27
Range 16-41 19-56
ays to ANC* >500/mm3
Median 11 12
Mean 11 13
Range 6-16 10-21yAbsolute neutrophil count.auses of NRM in the PO Bu group included 4 cases
f mortality often associated with high-dose Bu, he-
atic veno-occlusive disease (VOD) in 1 case with
eath on day 42, and pulmonary failure due to cryp-
ogenic organizing pneumonia in 3 cases with death
ccurring on days 42, 159, and 234. The only other
eath not secondary to relapse in the PO group was
rom acute congestive heart failure, possibly also reg-
men related, with death on day 72. The 1 case of
RM in the PKD IV group was due to a cerebral
emorrhage on day 48 in a 66-year-old patient on
nticoagulation for deep venous thrombosis.
elapse and Relapse-Related Mortality
Twenty-four patients had recurrence of their dis-
ase (10 of 18 patients in the PO Bu group and 14 of
1 in the PKD IV group; P  .48, chi-square test).
hese relapses occurred a median of 7 months after
utoHSCT. The distribution of time to relapse in the
groups was not different (Figure 2). There was only
relapse after 2 years in each group, at 47 months in
he PO group and at 28 months in the PKD IV group.
umulative incidences of relapse censoring early
eaths were 75% in the PO group and 48% in the
KD IV group (P  .11, log-rank test). Nineteen of
he 24 relapsed patients have died, 11 of 14 patients in
he PKD IV Bu group and 8 of 10 patients in the PO
u group. The median-conﬁrmed disease-free fol-
ow-up of the 16 surviving patients without relapse in
he PKD IV Bu group is 40 months (range, 19-69
onths) and that of the 3 surviving patients without
elapse in the PO Bu group is 95 months (range,
4-116 months).
S and PFS
Five patients (28%) treated with the PO Bu regi-
en are alive, with a median follow-up of survivors of
years (range, 7 to 11 years). Nineteen patients (61%)
reated with the PKD IV regimen are alive, with a
edian follow-up of survivors of 4 years (range, 2 to 6
able 3. Causes of Death after AutoHSCT of 49 Patients with
ntermediate- and High-Risk NHL Undergoing HSCT with PKD
V Bu in the BuCyE Preparative Regimen
PKD IV
(n  31)
PO
(n  18)
verall mortality 10 (32%) 13 (72%)
elapse mortality 9 8
RM 1 (3%)* 5 (28%)
ause of NRM
VOD 0 1 (day 42)
Cardiac disease 0 1 (day 72)
Pulmonary disease 0 3 (days 42, 159, 234)
Cerebral hemorrhage 1 (day 48) 0
P  0.01 versus PO.ears). The actuarial 5-year OS for patients treated
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Autologous HSCT for NHL with IV Busulfan 775ith the PO Bu regimen is 28%, whereas that for the
1 patients treated with the PKD IV Bu regimen is
8% (Figure 2; P  .010, log-rank test). The actuarial
FS values are 17% for patients in the PO Bu group
nd 50% for those in the PKD IV Bu combination
roup (Figure 2; P  .008, log-rank test).
ISCUSSION
High-dose chemotherapy supported by autoHSCT
s being used with increasing frequency as a treat-
ent modality for patients with NHL [9] since the
arma Trial published in 1995 [4]. The most com-
only used preparative regimens are based on BCNU
ontaining also cytosine arabinoside and melphalan
BEAM) [5,36], cytosine arabinoside and Cy (BEAC)
4,37], or just Cy (CBV) [38,39]. AutoHSCT is the
tandard of care for patients with aggressive variants of
HL who are refractory to primary therapy or have
elapsed after initial chemotherapy, but whose disease
emains sensitive to chemotherapy as evidenced by
esponse to “salvage” chemotherapy (ASBMT inter-
ediate-risk patients) [40]. A recent study by Bhatia et
l [41] for the Bone Marrow Transplant Survivor
tudy documented a signiﬁcantly increased late NRM
fter autoHSCT for hematologic malignancy with
(a) Overall Survival of AG-NHL Patients
0 25 50 75 100 125 150
0
10
20
30
40
50
60
70
80
90
100
Oral Bu
PKD IV B
p=0.01058%
28%
Months Post Tx
P
er
ce
n
t 
su
rv
iv
al
(b) Progression  Free Survival of AG-NHL Patients
0 25 50 75 100 125
0
10
20
30
40
50
60
70
80
90
100
Oral Bu
PKD IV B
p=0.008
50%
17%
Months post Tx
P
er
ce
n
t 
su
rv
iv
al
igure 2. (a) OS, (b) PFS, and (c) relapse rate after autoHSCT in 49
V Bu in the BuCyE preparative regimen. AG indicates aggressiveCNU-based regimens that was not observed with pu- or TBI-based regimens. This ﬁnding supports the
earch for safer and equally effective preparative reg-
mens.
In this study we compared the outcomes of 2
onsecutive cohorts of patients with ASBMT interme-
iate- and high-risk status at transplantation for ag-
ressive NHL who received an autoHSCT at our
enter using the intensive Bu-based regimen of
uCyE [17]. The ﬁrst cohort of patients received PO
u at 1 mg/kg for 16 doses and the second cohort
eceived IV Bu with increasingly sophisticated PK
onitoring to a target AUC of 1250 M/min for 16
oses. These 2 cohorts were comparable in terms of
ll known risk factors for autoHSCT outcome includ-
ng the more recently deﬁned International Prognos-
ic Index score determined before salvage chemother-
py [35].
The dramatically improved outcomes with the
KD IV Bu combination preparative regimen in this
istorically controlled study resulted primarily from a
ecreased Bu-associated regimen-related mortality
nd are thus most likely directly related to the use of
KD dosing and the ability to maintain a Bu AUC
etween 1000 and 1500 mol/min [27,28]. This re-
roducible PK proﬁle of IV Bu is in sharp contrast to
he reported erratic and unpredictable PK values re-
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C. Aggarwal et al.776limination of fatal hepatic VOD and pulmonary mor-
ality in addition to the lower relapse rate can be
irectly attributed to the PKD Bu administration and
esulted in a statistically signiﬁcant improvement in
S and PFS.
The lower incidence rate of VOD with IV Bu in
he BuCy preparative regimen has been noted in other
tudies [43,44]. Mortality from pulmonary toxicity was
lso eliminated with the switch to PKD IV Bu in this
tudy. Although less well studied because of lack of
recise diagnostic deﬁnition and variable time to on-
et, pulmonary toxicity contributed to dose-limiting
oxicity in the original phase 1 and later trials of
ose-escalated Bu in the BuCy regimens reported by
antos et al [11] and Tutschka et al [45]. Likewise, the
ower relapse rate observed with PKD IV Bu in our
tudy, although not statistically signiﬁcant, may be
eal and might be expected with good PK control.
ven in the allogeneic HSCT setting, it has been
ossible to show that low AUC for Bu in preparative
egimens is associated with high relapse rates after
SCT in chronic myeloid leukemia [22] and pediatric
alignancies [23].
Our results with PKD IV Bu in this regimen
ppear to be superior to any reported results with
CNU- or TBI-based regimens in comparable-risk
atients and even in trials including only sensitive-
elapse patients. Vose et al [9] recently published re-
ults of autoHSCT in 429 intermediate-risk patients.
t 3 years, the OS was 44% and the PFS was 31%. A
reliminary review of raw data on patients selected
rom the CIBMTR [10] who were never in remission
r underwent transplantation after relapse and were
reated with different preparative regimens found that
072 were treated during the same period. The pa-
ients in this review had OSs of 49% at 3 years and
4% at 4 years. However, direct comparisons remain
ifﬁcult because of multiple unknown or incompara-
le factors.
In summary, decreased NRM after the substitu-
ion of PKD IV Bu for PO Bu in this very intensive
uCyE regimen appears to be responsible for better
S and better PFS. This PKD IV BuCyE regimen is
safe and highly effective preparation for autoHSCT
n patients with NHL. Further investigation is war-
anted.
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